Cytokines, autoantibodies and astrocytes in the pathology of Aicardi-Goutieres syndrome (AGS)

• Conditions: congenital brain inflammation; congenital encephalopathy; 10047954; 10052635; 10007951

• Registration Number: NL-OMON34842
• Lead Sponsor: niversitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

AGS as diagnosed by pediatric neurologist

Exclusion Criteria

no similarity to AGS

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>We have previously shown that this test helps to discriminate AGS from viral<br /><br>disease. This current study will expand these data by screening blood and CSF<br /><br>from AGS patients and controls for a more extensive set of cytokines,<br /><br>chemokines and growth factors using available Luminex technology.<br /><br><br /><br>Primary outcome measures:<br /><br>- new sensitive diagnostics for AGS in blood and/or CSF<br /><br>- determine the sensitivity of these parameters over time (since the<br /><br>inflammatory features in AGS ultimately wane [burning out])<br /><br>- serum autoantibodies against standard autoantigens and tissue materials<br /><br>(routine diagnostics, including brain)<br /><br>- assess the time course of cytokines and presence or appearance of<br /><br>autoantibodies in relation to clinical disease</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>